MGMT and central nervous system cancer: To represent intertumoral heterogeneity and drug-resistant glioma cells, we used NHAs, commercial glioma cells (MGMT-methylated and -unmethylated), and patient-derived GSCs with proneural, classic, or mesenchymal molecular classifications and MGMT-methylated or -unmethylated statuses for the evaluation of PU-H71 against glioma.